Nikki Evensen

Nikki Evensen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti
TOTalia H. Ostrow
Talia H. Ostrow
SJSylwia Jasinski
Sylwia Jasinski
ERElizabeth A. Raetz
Elizabeth A. Raetz
WCWilliam L Carroll
William L Carroll
NENikki Evensen
Nikki Evensen
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and advances in its clinical and laboratory biology have grown exponentially over the last few decades. Treatment outcome has improved steadily with over 90% of patients surviving 5 years from initial diagnosis. This success can be attributed in part to the development of a risk stratification approach to identify those subsets of patients with an outstanding outcome that might qualify for a reduction in therapy associated with fewer short and long term side effects. Likewise, recognition of patients with an inferior prognosis allows for augmentation of therapy, which has been shown to improve outcome. Among the clinical and biological variables known to impact prognosis, the kinetics of the reduction in tumor burden during initial therapy has emerged as the most important prognostic variable. Specifically, various methods have been used to detect minimal residual disease (MRD) with flow cytometric and molecular detection of antigen receptor gene rearrangements being the most common. However, many questions remain as to the optimal timing of these assays, their sensitivity, integration with other variables and role in treatment allocation of various ALL subgroups. Importantly, the emergence of next generation sequencing assays is likely to broaden the use of these assays to track disease evolution. This review will discuss the biological basis for utilizing MRD in risk assessment, the technical approaches and limitations of MRD detection and its emerging applications.

24 April 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JPJoanna Pierro
Joanna Pierro
JSJason Saliba
Jason Saliba
SNSonali Narang
Sonali Narang
GSGunjan Sethia
Gunjan Sethia
SFShella Saint Fleur-Lominy
Shella Saint Fleur-Lominy
WCWilliam L Carroll
William L Carroll
The NSD2 p.E1099K (EK) mutation is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate clonal expansion, we engineered B-precursor ALL (B-ALL) cell lines (Reh, 697) to overexpress wildtype (WT) and EK NSD2, but observed no differences in proliferation, clonal growth, or chemosensitivity. To address whether NSD2 EK acts collaboratively with other pathways, we used short hairpin RNAs to knockdown expression of NSD2 in B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM). Knockdown resulted in decreased proliferation in all lines, decreased clonal growth in RCH-ACV, and increased sensitivity to cytotoxic chemotherapeutic agents, although the pattern of drug sensitivity varied among cell lines implying that the oncogenic properties of NSD2 mutations are likely cell context specific and rely on cooperative pathways. Knockdown of both Type II and REIIBP EK isoforms had a greater impact than knockdown of Type II alone, suggesting that both SET containing EK isoforms contribute to phenotypic changes driving relapse. Furthermore, in vivo models using both cell lines and patient samples revealed dramatically enhanced proliferation of NSD2 EK compared with WT and reduced sensitivity to 6-mercaptopurine in the relapse sample relative to diagnosis. Finally, EK-mediated changes in chromatin state and transcriptional output differed dramatically among cell lines further supporting a cell context–specific role of NSD2 EK. These results demonstrate a unique role of NSD2 EK in mediating clonal fitness through pleiotropic mechanisms dependent on the genetic and epigenetic landscape. Implications: NSD2 EK mutation leads to drug resistance and a clonal advantage in childhood B-ALL.

8 August 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ERElizabeth A. Raetz
Elizabeth A. Raetz
DTDavid T. Teachey
David T. Teachey
CMCharles Minard
Charles Minard
XLXiaowei Liu
Xiaowei Liu
RNRobin E. Norris
Robin E. Norris
WCWilliam L. Carroll
William L. Carroll

25 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SNSonali Narang
Sonali Narang
NENikki Evensen
Nikki Evensen
JSJason Saliba
Jason Saliba
JPJoanna Pierro
Joanna Pierro
MLMignon L. Loh
Mignon L. Loh
WCWilliam L Carroll
William L Carroll
The NSD2 p.E1099K (EK) mutation has been shown to be enriched in patients with relapsed ALL and found to play a role in clonal fitness dependent on the underlying genetic/epigenetic landscape of the cells. To uncover 3D chromatin architecture-related mechanisms underlying drug resistance, we systematically integrated Hi-C, ATAC-seq, RNA-seq and ChIP-seq data from three B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM) and assessed changes upon knockdown. NSD2 knockdown revealed widespread remodeling of the 3D genome, specifically in terms of compartmentalization. Systematic integration of these datasets revealed significant switches in A/B compartments with a strong bias towards B compartments upon knockdown, suggesting that NSD2 EK plays a prominent role in maintaining A compartments through enrichment of H3K36me2 epigenetic marks. In contrast, we identified few changes in intra-TAD activity suggesting that the NSD2 EK impacts transcriptional changes through a remarkable dependence on compartmentalization. Furthermore, EK-mediated reorganization of compartments highlights the existence of a common core of compacting loci shared across the three cell lines that explain previously described phenotypes as well as serve as targets for therapeutic intervention. This study offers a novel mechanism by which NSD2 EK drives clonal evolution and drug resistance.

20 May 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PPPallavi M. Pillai
Pallavi M. Pillai
NMNicole Mallory
Nicole Mallory
JPJoanna Pierro
Joanna Pierro
JSJason Saliba
Jason Saliba
DNDaniel Newman
Daniel Newman
NENikki Evensen
Nikki Evensen

24 October 2023 in Leukemia & Lymphoma
Verified
Journal Article
Open access
GYGloria P. Contreras Yametti
Gloria P. Contreras Yametti
GRGabriel Robbins
Gabriel Robbins
ACAshfiyah Chowdhury
Ashfiyah Chowdhury
SNSonali Narang
Sonali Narang
TOTalia H. Ostrow
Talia H. Ostrow
WCWilliam L Carroll
William L Carroll
Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response to thiopurines using CRISPR-mediated knockout in wild-type B-ALL cell lines. Likewise, restoration of SETD2 in cell lines with hemizygous mutations did not increase sensitivity. SETD2 mutations affected the chromatin landscape and transcriptional output that was unique to each cell line. Collectively our data does not support a role for SETD2 mutations in driving clonal evolution and relapse in B-ALL, which is consistent with the lack of enrichment of SETD2 mutations at relapse in most studies.